Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 16 — EQRx plots radical disruption on pricing

Biotechnology
Simon Wentworth
22 July 2022
episode16_big


More on this story...

Biotechnology
Focus on access helps EQRx find receptive audience in the UK
20 October 2021
Biotechnology
1 Year on, EQRx adds $500 million in Series B financing
11 January 2021
Biotechnology
CStone up on deal with EQRx for two immune checkpoint Inhibitors
27 October 2020
Biotechnology
EQRx releases positive Phase III trial data on sugemalimab
8 August 2022


Companies featured in this story

More ones to watch >


Today's issue

Nektar sells its PEGylation reagent manufacturing business
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024
Ascendis and Novo Nordisk sign deal on metabolic and CV diseases
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze